abbvie

Solarvest Web Site Launched in Hong Kong to Service South Easy Asia

(TheNewswire)



TheNewswire - December 1st 2021 Solarvest BioEnergy Inc. ("Solarvest" or the "Company") (TSXV:SVS)

Solarvest is pleased to announce that the Eversea TM Asian site has been launched on OrgHive's e-commerce platform.  The OrgHive/Eversea site has also been translated to Chinese for the convenience of OrgHive's 23 million unique organic-oriented customers.  Customers in China can now access detailed information on the world's first organic certified DHA product along with the chemical-free, clean label messaging. The e-commerce portal has also been configured and implemented.

Link https://eversea.orghive.com/

In addition, OrgHive and Eversea have developed a messaging program to promote/educate customers, on popular Chinese social media platforms, about the advantages of organic certified algae Omega-3. Fish oil is an established category and until now there has been no alternative that provides the assurance of product(s) that avoid environmental contamination and industrial chemical processing. The messages are designed to promote organic algae as a superior source of Omega-3, the importance of Omega-3 for brain health/growth, and general education on the types of Omega-3 with emphasis on the superior nature of long-chain Omega-3 (e.g. ALA vs. DHA).

The seeding/ promotional program will continue for the next few weeks while the company sets up branded Chinese social media accounts and phases in the Eversea specific promotion. The company has produced inventory earmarked for China. Concurrently, Eversea is contracting out the companies line of functional shots and, soon after, the powder products, both previously announced.

About OrgHive

The OrgHive organic community has garnered 23 million unique users since inception last year. They provide organic related content to consumers online and have developed a blockchain-based verification system for organic products that are purchased throughout mainland China. Furthermore, the platform developed by OrgHive will reach organic consumers beyond China, including those located in other parts of Asia. There are no commercial or regulatory barriers for Ever-sea to sell its products to Chinese consumers through OrgHive's online platform.

OrgHive will promote Eversea's algae-based, certified organic Omega-3 DHA, the first of its kind in the world, to millions of its registered subscribers. OrgHive will be responsible for logistics, fulfillment and all digital marketing activities, including social media.

About Solarvest

Solarvest BioEnergy Inc. is an algae biologics company whose production platform provides it with an extremely flexible system capable of producing numerous products from Omega 3 fatty acids to human therapeutic proteins. The Company has successfully developed, patented and produced the world's only plant-based organic certified Omega-3 to satisfy the substantial demand for this essential nutrient.  The Company has also initiated a program for the expression of CBD and THC to be produced in GMP fermentation facilities.

For further information contact:

Gerri Greenham

Tel: (647) 204-4095

Email: invest@solarvest.ca

Forward-Looking Statement

This news release contains forward-looking statements, which relate to future events or future performance and reflect management's current expectations and assumptions. Such forward-looking statements reflect management's current beliefs and are based on assumptions made by and information currently available to the Company. Investors are cautioned that these forward looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected. These forward-looking statements are made as of the date hereof and, except as required under applicable securities legislation, the Company does not assume any obligation to update or revise them to reflect new events or circumstances.

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Copyright (c) 2021 TheNewswire - All rights reserved.

News Provided by TheNewsWire via QuoteMedia

The Conversation (0)
Radiopharm Theranostics

Investor Webinar – 3pm AEST Tuesday 2 July

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that CEO and Managing Director Riccardo Canevari and Executive Chairman Paul Hopper will conduct an investor webinar to provide an update following announcement of the Company’s $70 million capital raising.

When: 3pm AEST, Tuesday 2 July 2024

Keep reading...Show less
Researcher in medical lab looking at sample with microscope.

Oncology Stocks: 8 Biggest NASDAQ Companies in 2024

The wide-ranging oncology market covers every area of cancer care, from diagnosis to treatment.

Coming in only after cardiovascular disease, cancer is the second leading cause of death worldwide; unsurprisingly, oncology is one of the biggest sectors in the life science space. With that in mind, biotechnology and pharmaceutical companies alike are working to develop best-in-class therapeutics for the treatment of various cancers, including lung, breast and prostate cancer.

At this point, their work is far from finished — Fortune Business Insights projects that the global oncology market will increase at a compound annual growth rate of 11.3 percent to reach US$518.25 billion in 2032.

As the global oncology market grows, investors who want exposure to companies working to treat cancer should consider taking a look at biotech and pharma companies with a focus on oncology drugs and testing.

Keep reading...Show less
Radiopharm Theranostics

Radiopharm Theranostics Limited (ASX: RAD) – Reinstatement to Quotation

Description

The suspension of trading in the securities of Radiopharm Theranostics Limited (‘RAD’) will be lifted immediately following the release by RAD of an announcement regarding its capital raising.

Keep reading...Show less
Radiopharm Theranostics

Radiopharm Theranostics Completes A$70 Million Placement

Radiopharm Theranostics Limited (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, has received firm commitments to raise approximately A$70.0 million (before costs) by way of a placement (the Placement) comprised of international and Australian institutional and industry investors, including Lantheus Holdings (“Lantheus”) and specialist US healthcare investors.

Keep reading...Show less
Radiopharm Theranostics

Radiopharm Receives Strategic Investment for up to A$18 million

Radiopharm Theranostics Limited (ASX:RAD) (Radiopharm or the Company), a developer of diagnostic and therapeutic radiopharmaceutical products, has entered into strategic agreements with Lantheus Holdings, Inc. (LNTH.NASDAQ), a leading radiopharmaceutical-focused company, and its affiliates (Lantheus). Lantheus has agreed to make an initial equity investment of A$7.5 million (US$4.99 million) and will have an option to invest a further A$7.5 million (US$5 million) within 6 months on the same terms. Additionally, Radiopharm has agreed to transfer two of its early preclinical assets to Lantheus for A$3.0 million (US$2.0 million) pursuant to a separate transfer and development agreement.

Keep reading...Show less
Radiopharm Theranostics

Radiopharm Theranostics Limited (ASX: RAD) – Trading Halt

Description

The securities of Radiopharm Theranostics Limited (‘RAD’) will be placed in trading halt at the request of RAD, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 24 June 2024 or when the announcement is released to the market.

Keep reading...Show less

Latest Press Releases

Related News

×